Search results

More info coming soon! More info on the NARILIS website

Thematic sessionsThe day will be organized in two thematic sessions:Cancer metabolismNew advances in cancer therapyInvited speakersProf. Rebecca FITZGERALD, Early Cancer Institute, University of Cambridge, UKDr. Sébastien DUTERTRE, IBMM, University of Montpellier, FranceProf. Sarah-Maria FENDT, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven, BelgiumDr. Arnaud BLOMME, Laboratory of Metabolic Regulation, GIGA Institute, University of Liège, Belgium Call for communicationsYoung researchers are invited to submit abstracts for oral communications and posters. All topics related to the field of cancer research are welcome. The deadline for abstract submission is April 1, 2025. Organizing committeeProf. Jean-Pierre Gillet - UNamur, NARILIS, Laboratory of Molecular Cancer BiologyProf. Marc Hennequart - UNamur, NARILIS, Laboratory of Cancer metabolismProf. Marielle Boonen - UNamur, NARILIS, Laboratory of Intracellular Trafficking BiologyProf. Benjamin Beck - ULB, IRIBHMProf. Lionel D'Hondt - CHU UCL Namur, Department of Oncology More info

Target audienceGeneral practitioners (in practice or in training)PharmacistsMedical and pharmacy studentsObjectivesShare and discuss scientific articles relevant to frontline practice in a friendly and caring atmosphereStrengthen skills in critical reading and evidence-based medicineCreate a lasting link between the field and the academic worldFederate an active and committed medico-pharmaceutical community.pharmaceutical communityWhy participate?Because science moves fast, and we all benefit from taking the time to read, understand, and question the literature together. Because quality care starts with shared reflection. And because it's the ideal opportunity to strengthen bridges between disciplines.Location and frequency of meetingsUNamur - Quai22 - 2 times a yearFirst meeting: 5/06/2025 (free with registration)INAMI accreditation required. I want to register

The program 2:00 pm | Keynote lecture on the use of AI in research - Hugues BERSINI, Professor at the Université libre de Bruxelles: "Can science be just data driven?" 3:00 pm | Presentations by UNamur researchers3:00 pm | Catherine Guirkinger: Use of AI in an economic history project3:15 pm | Nicolas Roy (PI: Alexandre Mayer): AI at the service of innovation in photonics and optics: revealing the secrets of scrolls through the classification of animal species15:25 | Nemanja Antonic (PI: Elio Tuci): An in silico representation of C. elegans collective behaviour<15h35 | Nicolas Franco : The benefits and dangers of "predicting the future" with covid-like machine learning models 15h45 | Michel Ajzen : Managerial and human implications of AI in organizations <15h55 | Robin Ghyselinck (PI : Bruno Dumas) : Deep Learning for endoscopy: towards next generation computer-aided diagnosis4:05 pm | Auguste Debroise (PI : Guilhem Cassan) : LLMs to measure the importance of stereotypes within gender representations in Hollywood films16h15 | Gabriel Dias De Carvalho : Learning practices in physics using generative AI16h25 | Sébastien Dujardin (PI : Catherine Linard) : Where Geography meets AI: A case study on mapping online flood conversations16h35 | Jeremy Dodeigne : LLMs in SHS: revolutionary tools in a Wild West Territory? Reflections on costs, transparency and open science16h45 | Antoinette Rouvroy : Governing AI in Democracy17h00 | Keynote lecture on ethics and guidelines to consider when using AI in research projects and writing research articles - Bettina BERENDT, Professor at KU Leuven18h00 | Benoît Frenay and Michaël Lobet : Creation of an IA scientific committee at UNamur18:10 | DrinkA certificate of attendance, worth 0.5 cross-disciplinary doctoral training credits, will be issued on request. Contact: secretariat.adre@unamur.beThis event is free of charge, but registration is required. I want to register

Program Overview This event will take place over two exciting days, featuring a diverse program designed to offer a dynamic and interactive experience for all participants. The entire symposium will be conducted in English.On Wednesday, December 9, and Thursday, December 10, two days of scientific and technical sessions will be dedicated to the topics of alternative proteins, the microbiome, and functional ingredients.On Wednesday, December 9, there will be a public lecture (in English) presented by Dr. Patrice Cani on the topic “Nourishing Your Gut: Nutrition, Microbiota, and Health.”For experienced researchers and group leaders, we are organizing a third day on December 11 dedicated to international collaboration, including laboratory visits and a workshop focused on establishing structured collaborative projects. Separate registration is requiredOverview of the ThemesThis symposium is structured around the three projects in the FoodWal portfolio, while pushing their boundaries and framing them within a “One Health” approach.The session titled “Building Sustainable Value Chains for Alternative Proteins: from protein sources to the development of healthy food products” will provide an opportunity to present scientific and technological advances in the creation and characterization of alternative protein sources and products, as well as socioeconomic perspectives on the development, maintenance, and growth of sustainable value chains for alternative proteins.The session titled “Research on the Microbiome and Microbiotics: Innovation in Nutrition for Better Health” will present scientific advances in the characterization, understanding, and modulation of the microbiome, as well as cutting-edge technologies aimed at developing innovative microbiotics.Finally, the session titled “Functional Ingredients and Bioactive Compounds: Food Science and Biotechnology for Health” will focus on scientific advances in the identification, characterization, and understanding of the mechanisms of action of functional ingredients, as well as cutting-edge technologies designed to develop and produce innovative functional ingredients. More information on the FoodWal website Je m'inscris

JuryProf. Steve LANNERS (UNamur), ChairProf. Johan WOUTERS (UNamur), SecretaryProf. Pierre FRANCOTTE (ULiège)Dr. Marie HAUFROID (UCB)Prof. Lionel POCHET (UNamur)AbstractCurrently, Mycobacterium tuberculosis remains the second deadliest infectious agent in the world, responsible for 1.6 million deaths in 2021. The burden and cost of current treatment (6 months and 4,000 euros), coupled with the alarming emergence of antibiotic-resistant strains, underscore the absolute urgency of developing new therapeutic molecules. This study focuses on the Mycobacterium tuberculosis phosphoserine phosphatase (MtSerB2), an enzyme essential for serine biosynthesis and vital to the pathogen’s survival. Furthermore, this protein plays a key role in host invasion (through its interactions with the NF-κB factor and the cellular cytoskeleton), making MtSerB2 a prime therapeutic target for the development of new, potent anti-tuberculosis drugs.One of the innovative strategies explored in this thesis is based on destabilizing the protein’s structure (disruption of protein structure). The goal is to design a molecule capable of disrupting the enzyme’s conformation, thereby causing it to lose its catalytic activity. This new class of molecules is expected to exhibit significantly higher selectivity for MtSerB2 compared to its human homolog, human phosphoserine phosphatase (hPSP).To this end, the Mycobacterium avium phosphoserine phosphatase (MaSerB) was initially used as a model system, justified by its 83% sequence identity with MtSerB2 and its propensity to crystallize rapidly. Initially, a virtual screening of drugs already available on the market was conducted to identify potential inhibitors of MaSerB. Enzymatic assays based on malachite green detectionwere then performed to evaluate the inhibitory activity of the various candidates. The results demonstrated increased selectivity of these compounds for dimeric proteins (MtSerB2 and MaSerB) compared to the human enzyme hPSP.Notably, subsequent enzymatic assays conducted directly on MtSerB2 revealed response profiles that differed from those observed with the MaSerB model. To elucidate the molecular basis of these differences, the structure of the protein in its ligand-bound state is currently being investigated. To this end, protein-inhibitor complexes have been crystallized and will be analyzed by X-ray diffraction.

Abstract Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous malignancy in which human papillomavirus (HPV) status strongly influences therapeutic response. HPV-positive tumors generally show greater sensitivity to treatment, whereas HPV-negative tumors are associated with a poorer prognosis and increased resistance. This thesis investigated how HPV status shapes cellular adaptation to therapeutic stress, with a particular focus on therapy-induced senescence (TIS), autophagy, and MMS19.HPV- HNSCC cells developed a senescence-like phenotype following cisplatin or X-ray irradiation, whereas HPV+ cells showed limited induction. Silencing of the viral oncogenes E6 and E7 in HPV-positive cells enhanced this phenotype, indicating that HPV actively modulates treatment-induced cellular responses. Proteomic analyses further identified autophagy- and lysosome-related pathways as major features distinguishing HPV- from HPV+ cells. Autophagy inhibition predominantly impaired proliferation and clonogenic survival in HPV- cells, supporting an HPV-dependent autophagy–senescence axis involved in treatment adaptation.The second part of this thesis identified MMS19, a component of the cytosolic iron–sulfur cluster assembly machinery, as a potential determinant of HPV- HNSCC resistance. MMS19 was associated with poorer clinical outcomes, while its silencing impaired proliferation and clonogenic survival, particularly in HPV- cells.Together, these findings identify autophagy-dependent remodeling and MMS19-associated genome maintenance as potential vulnerabilities contributing to therapeutic resistance in HPV- HNSCC. Jury Prof. Anne-Catherine HEUSKIN (UNamur), ChairProf. Carine MICHIELS (UNamur), SecretaryProf. Francis RODIER (UMontreal)Prof. Yves POUMAY (UNamur)Prof. Anabelle DECOTTIGNIES (UCLouvain)Prof. Marc THERRIEN (University of Montreal)Prof. Sue YOM (UCSF)

AbstractPopulation aging is accompanied by an increase in the prevalence of neurodegenerative diseases, including tauopathies. This family of diseases, which includes Alzheimer’s disease, is characterized by the mislocalization, hyperphosphorylation, and accumulation of the tau protein in a pathological form, leading to neuronal dysfunction and ultimately neuronal death within the central nervous system. Numerous studies conducted in humans and in various animal models have demonstrated an association between repeated head trauma and the development of a specific tauopathy, chronic traumatic encephalopathy. This progressive neurodegenerative disease is attributed to repeated exposure to impacts to the head that generate acceleration-deceleration forces in the brain.Although the brain and spinal cord share many cellular and tissue characteristics, the consequences of spinal cord trauma on the development of tauopathies remain largely unexplored. To investigate this question, a new mouse model of repeated mild spinal cord trauma was developed in the PS19 mouse, a transgenic model of tauopathy that replicates several characteristics of frontotemporal dementia. Two low-intensity spinal cord contusions (30 kDynes), administered three weeks apart, were performed at two months of age to assess their impact on the long-term progression of the disease.Although these injuries induce neither immediate clinical deficits, nor detectable tissue lesions, nor neuronal loss, they elicit a marked glial response as well as neuronal and axonal damage, as evidenced by increased circulating concentrations of neurofilament light chains. Longitudinal follow-up of the animals revealed an earlier onset of motor and sensory deficits, associated with an accelerated decline in their overall health.In the short term (3.5 months), no worsening of tauopathy was observed. However, at 6.5 months of age, a significant increase in the density of hyperphosphorylated forms of tau, detected by the pTau(Ser202/Thr205) and pTau(Ser422) antibodies, was observed near the epicenter of the lesion in the contusion-injured animals. By 9 months, this exacerbation of the pathology had spread along the rostral-caudal axis, between spinal cord segments C2 and C7, as well as to the thalamus. Although spinal cord injuries did not alter Tau protein aggregation, in vitro analyses showed that the insoluble protein fraction extracted from the spinal cord of contusion-injured animals possessed greater recruitment capacity.Although no direct causal link could be established, histological, biochemical, and transcriptomic analyses suggest the involvement of microglia, type I interferon signaling, and the p38 MAP kinase pathway in stimulating Tau hyperphosphorylation.Taken together, these results highlight a previously largely underestimated role of mild spinal cord injuries as a factor promoting the development and progression of tauopathies. They also reinforce existing literature suggesting that neuroinflammation—and more specifically, microglial activation and type I interferon signaling—contributes to the progression of these diseases. Finally, this study underscores the importance of long-term follow-up for individuals exposed to spinal cord injuries—even mild ones—due to the potential increased risk of developing neurodegenerative diseases involving the Tau protein.JuryProf. Pascal KIENLEN-CAMPARD (UCLouvain)Prof. Karelle LEROY (ULB)Prof. Aurélie LADANG (ULiège)Prof. Charles NICAISE (UNamur)Prof. Patsy RENARD (UNamur), ChairProf. Laurence RIS (UMons)

AbstractFrequently touched surfaces (fomites) serve as reservoirs for pathogens, including bacteria and viruses, and act as vectors for contact-mediated transmission. They contribute to the spread of healthcare-associated infections and pose an increased risk during epidemic outbreaks, as highlighted by the COVID-19 pandemic. This thesis focuses on the development of antimicrobial coatings that release silver (Ag) and copper (Cu), deposited by magnetron sputtering. Three coating matrices were investigated: hydrogenated amorphous carbon with or without chromium (a-C:H and Cr/CrN/a-CrC:H) and titanium aluminum nitride (TiAlN).Antibacterial performance was evaluated against Staphylococcus aureus and Escherichia coli. To assess long-term efficacy, the antibacterial properties of the coatings were investigated through successive bacterial exposure cycles. Antiviral activity was evaluated against porcine respiratory coronavirus (PRCV), a member of the Orthocoronavirinae subfamily to which SARS-CoV-2 also belongs. For this purpose, a rapid, high-throughput antiviral screening assay was developed. This innovative method represents a promising approach for the standardized evaluation of antiviral surfaces. In addition to antimicrobial activity, the coatings were required to exhibit adequate mechanical properties and an attractive black appearance suitable for high-touch surfaces.The combination of Ag and Cu exhibited a synergistic effect, enhancing antimicrobial activity and broadening the spectrum of targeted pathogens. Optimization led to a TiAlN coating containing 0.9 at.% Ag and 1.7 at.% Cu, which provided the best balance between mechanical, antibacterial, and antiviral performance. Tribological wear tests confirmed that its antimicrobial efficacy was maintained for up to two years. Prospects for the further development and scientific validation of this prototype are discussed.JuryProf. Benoît MUYLKENS (UNamur), ChairProf. Stéphane LUCAS (UNamur), SecretaryProf. Jean-Michel DOGNÉ (UNamur)Prof. Philippe STEYER (INSA Lyon, University of Lyon)Dr. Sébastien PENNINCKX (UNamur)Dr. Emile HAYE (Innovative Coating Solutions)